WJOG6510GTR: Study of genetic biomarkers to predict efficacy in patients with wild-type KRAS metastatic colorectal cancer receiving Panitumumab + Irinotecan or Cetuximab + Irinotecan

WJOG6510GTR: Study of genetic biomarkers to predict efficacy in patients with wild-type KRAS metastatic colorectal cancer receiving Panitumumab + Irinotecan or Cetuximab + Irinotecan - WJOG6510GTR: Study of genetic biomarkers to predict efficacy in patients with wild-type KRAS metastatic colorectal cancer receiving Panitumumab + Irinotecan or Cetuximab + Irinotecan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008786

Enrollment

120

Registered

2012-08-28

Start date

2013-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who participate in the WJOG6510G and give informed consent to the current study are qualified.

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
To evaluate the correlation between the efficacy or safety and the genetic polymorphism in patients with cetuximab plus irinotecan or panitumumab plus irinotecan therapy.	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group datacenter

datacenter@wjog.jp06-6633-7400

Outcome results